Spotlight on Clinical Trials
A Randomized Phase 2 Placebo-Controlled Study of LY2495655 in Patients with Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy
LY2495655 (LY) is a humanized monoclonal antibody manufactured by Eli Lilly that may have activity against certain pancreas cancers when given in combination with standard chemotherapy.
This study is for patients with advanced or metastatic pancreas cancer (cancer of the pancreas that cannot be removed by surgery and/or has spread to other parts of the body). The purpose of this study is to see how safe the investigational drug, LY, is and how well it will work to help people with advanced or metastatic pancreas cancer fight the disease. The primary purpose of this study is to answer the following research questions:
- How safe is this antibody?Â Are any side effects observed that might be LY-associated when given in combination with chemotherapy?
- Can this antibody help patients with cancer of the pancreas fight the disease?
- Can this antibody help patients with cancer feel stronger and more active?
All subjects who participate in this study will receive standard chemotherapy for their pancreas cancer. They will be randomized (like the flip of a coin) to receive one of two doses of LY or placebo (meaning no active medicine) with their standard chemotherapy.
See http://lombardi.georgetown.edu/clinicalprotocols/index.cfm for further trial details.